NEW YORK--(BUSINESS WIRE)--Sixpoint Partners, a leading global investment bank serving the middle market, announced today the successful closing of Sheridan Capital Partners Fund III, L.P. (together with its parallel fund, “Fund III” or the “Fund”), at the hard cap with $575 million of total capital commitments.
The Fund was oversubscribed, significantly exceeding its target of $450 million despite the challenging fundraising environment. Sheridan Capital Partners (“Sheridan”) is focused on making investments in lower middle market companies in recession resistant, non-discretionary markets within the healthcare industry. The Fund will continue Sheridan’s strategy of making control investments in North American founder-owned businesses with $3-20 million of EBITDA. Sheridan is led by Partners Jonathan Lewis and Sean Dempsey.
“We deeply value the support we received from our existing investor base for this fundraise, as well as the new strategic partnerships we have created in Fund III, which further diversify our high-quality group of insurance companies, consultants, pensions, family offices, sovereign wealth funds and fund-of-funds across North America, Europe and the Middle East,” said Jonathan Lewis, Partner at Sheridan.
“It has been a great partnership working with Sixpoint on another successful fundraise and we’d like to thank them for their continued commitment and strategic advice,” stated Sean Dempsey, Partner at Sheridan. “We’d also like to thank our limited partners for their critical role in closing Fund III at $575 million. We are very excited about the next phase of growth for our firm as we continue to expand both our team and presence in lower middle market healthcare.”
“We are extremely pleased to have worked with Jonathan, Sean and the rest of the Sheridan team again to help them achieve their second oversubscribed fundraise in a highly competitive environment. This is another example of Sheridan’s continued reputation as a leader in the lower middle market healthcare space,” said Eric Zoller, Founder & Partner at Sixpoint Partners.
“The global demand we saw in the fundraise from both new and existing investors shows the high level of conviction the market has for Sheridan’s team and strategy. We value the partnership and are excited to see the team continue to generate value for their investors,” said Matt Thornton, Partner at Sixpoint Partners.
About Sheridan Capital Partners
Sheridan Capital Partners is a Chicago-based healthcare private equity firm that focuses on lower middle market buyouts and growth equity in the U.S. and Canada. Sheridan partners with companies in the verticals of providers and provider services, healthcare IT and outsourced services, and consumer health and medical products, bringing strategic resources to accelerate growth, build enduring value, and achieve strong results. www.sheridancp.com
About Sixpoint Partners
Sixpoint Partners is a leading global investment bank focused on delivering strategic advisory and fundraising solutions for the middle-market private equity industry. The firm’s core areas of focus include (i) primary fund placement and strategic advisory, (ii) secondaries advisory and (iii) co-investment placement across a wide range of industries, strategies and geographies. Sixpoint Partners has a reputation for its direct, results-driven style and for delivering innovative solutions to complex problems in order to create long-term value for clients. Sixpoint is headquartered in New York with offices in Chicago, San Francisco and London. Investment banking and other advisory activities are provided by Sixpoint Partners LLC (“Sixpoint”) a registered broker-dealer and a member of FINRA and SIPC. For more information, please visit www.sixpointpartners.com.
Harris Williams, a global investment bank specializing in M&A advisory services, announced its pending merger with Sixpoint Partners in April 2023. The combined entity will provide clients with expanded advisory services including M&A, capital solutions and primary fund placement. The merger, which is expected to be completed this summer, is subject to receipt of regulatory approval.
